---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-031240"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:47:44.478446+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma reports positive clinical data for QRX003: skin healed, no adverse events in pediatric Netherton patient

## Summary
- After 6 weeks of daily whole-body QRX003, the pediatric Netherton patient's skin is almost completely healed.
- Patient no longer requires antibiotics, antivirals, antihistamines, or glucocorticoids; pruritus eliminated.
- Zero nightly sleep disturbances without sedating medication; first continuous uninterrupted sleep in patient's life.
- No adverse events reported after 6 weeks of whole body treatment with QRX003.
- Company expects to initiate whole body application on a second pediatric patient in a few weeks.

## SEC filing metadata
- accession: 0001104659-25-031240
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925031240/0001104659-25-031240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925031240/tm2511344d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-031240
- JSON: https://secwatch.observer/filing/0001104659-25-031240.json
- Plain text: https://secwatch.observer/filing/0001104659-25-031240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.